GlassScriptPhysician profile
Rahul K Reddy
NPI 1083806863
$332,752.82
in general payments reported to CMS, 2019-2025
18 companies · $19K in 2025
The $19K reported for 2025 was more than what 94% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82K · 2020: $61K · 2021: $53K · 2022: $42K · 2023: $13K · 2024: $63K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $50K · Royalty Or License: $44K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $50,000.00 |
| Royalty Or License | $44,397.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $82,547.06 | 2019-2024 | |
| Bausch & Lomb Americas INC. | $55,057.64 | 2022-2025 | Ophthalmic Instruments |
| Regeneron Healthcare Solutions, INC. | $44,097.02 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $40,220.20 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $35,620.05 | 2019-2021 | |
| Eyepoint US, INC. | $35,133.96 | 2019-2022 | |
| Allergan, INC. | $23,796.24 | 2019-2021 | |
| Alimera Sciences, INC. | $10,171.92 | 2019-2022 | |
| Abbvie INC. | $5,159.65 | 2022 | |
| Carl Zeiss Meditec, INC. | $296.67 | 2019-2020 | |
| Dutch Ophthalmic, USA | $280.01 | 2019 | |
| Genentech USA, INC. | $241.21 | 2019-2022 | |
| Genentech, INC. | $96.61 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Alcon Vision LLC | $15.18 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$442,937.57 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.